US president Donald Trump on Tuesday announced the launch of a new federal website, TrumpRx.gov, as part of a deal with Pfizer to offer prescription drugs directly to consumers at discounted prices. The initiative, aimed at cutting healthcare costs, is expected to grow with more deals from other drugmakers in the coming months.The new website is part of a broader push to align US drug prices with those in other developed nations, a strategy known as “most-favored-nation” pricing. Under the deal, Pfizer agreed to offer the same prices for new drugs in both the US and other advanced markets.“The United States is done subsidizing the health care of the rest of the world,” Trump said in a press conference. “They put all of that on us, and yet they were the beneficiaries too. So it’s been changed.”A senior administration official said Tuesday that the TrumpRx site, set to launch in early 2026, will not directly sell or distribute medications. Instead, consumers will be able to search for their prescriptions and be redirected to drugmakers’ direct-to-consumer platforms, as cited by CNN.Pfizer said most of its primary care drugs will be offered through TrumpRx, though it did not specify which ones. The company also announced plans to invest an additional $70 billion (£52 billion) in US manufacturing, research, and development.“We now have the certainty and stability we need on two critical fronts, tariffs and pricing,” Pfizer’s chief executive, Albert Bourla, said, as reported by the BBC. According to a company press release, direct-to-consumer prices for Pfizer drugs on TrumpRx.gov will average 50 percent lower. However, key details on how those discounts were determined were not provided. “Specific terms of the agreement remain confidential,” the release stateThe administration on Tuesday clarified that “Most Favored Nation” pricing is based on a drug’s net price, including discounts and rebates, compared with the lowest price in other wealthy countries such as Canada, France, Germany, Italy, Japan, the UK, Switzerland, and Denmark. This lowest international price then serves as the benchmark for US pricing.Pfizer, the first drugmaker to fully meet the demands outlined in Trump’s July letter to industry CEOs, plans to offer Medicaid “Most Favored Nation” pricing starting in early 2026, with the president indicating other companies may follow.Trump has often highlighted that Americans pay significantly more for prescription drugs than people in other developed nations, especially in Europe, where governments frequently set prices. A Health and Human Services report last year found US drug prices to be nearly three times higher than in comparable countries. During his first term, Trump unsuccessfully pushed for a “Most Favored Nation” pricing policy to address the gap.
